Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-358-4 | CAS number: 13762-14-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Oral: After oral ingestion of soluble cobalt substances, absorption from the gastrointestinal tract increases with solubility of the cobalt substance and with iron deficiency of the individual. Studies in laboratory animals indicated increased cobalt levels primarily in liver, as well as in other organs. Orally administered cobalt is primarily eliminated in faeces.
Inhalation: Following inhalation exposure to soluble cobalt substances, large particles are deposited in the upper respiratory tract where they are subjected to mechanical clearance, including transfer to the gastrointestinal tract. Smaller particles are deposited in the lower respiratory tract where they may be solublised and absorbed, or phagocytosed. Following an initial high rate of faecal clearance, urinary excretion is the primary route of cobalt elimination after inhalation exposure.
Key value for chemical safety assessment
Additional information
There are no toxicokinetic studies available for cobalt molybdenum oxide. However, there are reliable data for soluble cobalt and molybdenum substances considered suitable for read-across using the analogue approach. For identifying hazardous properties of cobalt molybdenum oxide, the existing forms of cobalt molybdenum oxide at very acidic and physiological pH conditions are relevant for risk assessment of human health effects. Cobalt molybdenum oxide is a metal-organic salt, which is highly water soluble (~ 508 mg/L) and nearly completely dissociates in aqueous solutions. As it is expected that cobalt molybdenum oxide is capable of forming ions at very acidic and physiological pH conditions, cobalt cations and molybdate anions will be present and completely bioavailable, same as for other soluble cobalt and molybdenum compounds. Due to the existing cobalt and molybdate ions, data from other soluble cobalt and molybdenum substances are used in the derivation of toxicological endpoints for cobalt molybdenum oxide. For further details refer to the analogue justification.
Cobalt substances
Absorption
Oral: The absorption of cobalt salts after oral administration is dependent on their water solubility. Water soluble cobalt salts dissolve directly and have been found to exhibit greater absorption than non-water soluble compounds (Firriolo et al., 1999).
Studies on the absorption of cobalt(II)chloride in human volunteers indicate that the absorption rate from the gastrointestinal tract ranges from 5% to > 20%, depending on the dose and the nutritional status of the individual (Smith et al., 1972; Sorbie et al., 1971). Cobalt absorption was increased among individuals (humans and animals) who were iron deficient (31-71% absorption in iron-deficient subjects, 18-44% in controls) (Valberg et al., 1969; Sorbie et al., 1971). The gastrointestinal absorption is reduced when cobalt is administered after a meal (Midtgard and Binderup, 1994).
Inhalation: Inhalation of cobalt particles results in deposition in the upper and lower respiratory tract (Casarett and Doull, 1986). Particle size is the primary factor determining deposition patterns. Large particles (diameter > 2 µm) deposit in the upper respiratory tract, while smaller particles tend to deposit in the lower respiratory tract, where sedimentation and diffusion can occur. Fractional deposition varies due to particle size, age and breathing patterns of the exposed individuals. Cobalt particles deposited in the respiratory tract can be absorbed into the blood after dissolution, phagocytosed or mechanically transferred to the gastrointestinal tract by mucociliary action and swallowing (Foster et al., 1989).
Dermal: The available data indicate that the in-vivo dermal absorption rate in guinea pigs was in the same range as the in-vitro dermal absorption rate reported for humans (51-86 and 38 nmol/cm²/h, respectively; application of 0.085 M cobalt(II)chloride) (Wahlberg, 1965). Dermal exposure to cobalt(II)chloride may result in significant systemic uptake of cobalt.
Metabolism: The Co²+ cation is not subjected to any metabolism.
Distribution and excretion: The distribution of cobalt after oral administration in rats indicated that cobalt absorbed in the gastrointestinal tract is primarily retained in the liver. But cobalt was also found in the kidneys, heart, stomach, and intestines (Ayala-Fierro et al., 1999).
After inhalation exposure in animals, marked increases of cobalt have been found in the lung. Histological analysis revealed that cobalt particles were localised to macrophages within the bronchial wall or in the interstitium close to the terminal bronchiole. Cobalt has been found also in the liver, kidney, trachea, spleen, bones and heart with the highest level in the liver and kidney (Brune et al., 1980).
Animal data on cobalt elimination indicate that the solubility of the cobalt compound greatly affects the long-term clearance. Soluble cobalt compounds are absorbed into the blood at a faster rate than less soluble compounds and excreted in the urine and faeces (Barnes et al., 1976). Urinary excretion rates seem to correlate with the translocation rate of cobalt from the lungs to blood, whereas faecal excretion rates seem to correlate with mechanical clearance rates of cobalt from the lungs to the gastrointestinal tract (Collier et al., 1989; Patrick et al., 1989). Following an initial high rate of faecal clearance, urinary excretion is the primary route of cobalt elimination after inhalation exposure (Palmes et al., 1959).
After oral administration, faecal elimination is the primary route of excretion. Ayala-Fierro et al. (1999) showed that cobalt(II)chloride was excreted primarily via faeces in rats (70-83% of the administered dose), with urinary excretion for the remainder of the dose. Faecal clearance has been noted to decrease as cobalt particle solubility increases.
Following single intravenous administration of cobalt(II)chloride to rats, 10% of the dose was excreted in faeces indicating biliary excretion and 75% of the dose was excreted in urine 36 hours after administration (Ayala-Fierro et al., 1999).
References:
Casarett LJ and Doull J, 1986, The basic science of poisons, 3rd ed. New York , Macmillan Publishing Company, pp. 56-57
Foster PP et al., 1989, An interspecies comparison of the lung clearance of inhaled monodisperse cobalt oxide particles – Part II: Lung clearance of inhaled cobalt oxide in man. Journal of Aerosol Science, 20(2): 189-204
Firriolo JM et al., 1999, Absorption and disposition of cobalt naphthenate in rats after a single oral dose. Journal of Toxicology and Environmental Health A, 58: 383-395
Smith T et al., 1972, Absorption and retention of cobalt in man by whole-body counting. Health Physics, 22: 359-367
Sorbie J et al., 1971, Cobalt excretion test for the assessment of body iron stores. Canadian Medical Association Journal, 104(9): 777-782
Valberg LS et al., 1969, Alteration in cobalt absorption in patients with disorders of iron metabolism. Gastroenterology, 56(2): 241-251
Midtgard U and Binderup ML, 1994, The nordic expert group for criteria documentation of health risks from chemicals. 114. Cobalt and cobalt compounds. Arbete och Hälsa, 39: 1-66
Wahlberg J., 1965, Percutaneous absorption of sodium chromate (51Cr), cobaltous (56Co), and mercuric (203Hg) chlorides through excised human and guinea pig skin. Acta Derm Venerol, 45: 415-426
Brune D et al., 1980, Pulmonary deposition following inhalation of chromium-cobalt grinding dust in rats and distribution in other tissues. Scandinavian Journal of Dental Research, 88: 543-551
Ayala-Fierro F et al., 1999, Disposition, toxicity and intestinal absorption of chloride in male Fischer 344 rats. Journal of Toxicology and Environmental Health A, 56: 571-591
Barnes JE et al., 1976, Cobalt-60 oxide aerosols: Methods of production and short-term retention and distribution kinetics in the beagle dog. Health Physics, 30: 391-398
Collier CG et al., 1989, An interspecies comparison of the lung clearance of inhaled monodisperse cobalt oxide particles – Part V: Lung clearance of inhaled cobalt oxide particles in hamsters, rats and guinea pigs. Journal of Aerosol Science, 20(2): 233-247
Patrick G et al., 1989, An interspecies comparison of the lung clearance of inhaled monodisperse cobalt oxide particles – Part V: Lung clearance of inhaled cobalt oxide particles in SPF Fischer rats. Journal of Aerosol Science, 20(2): 249-255
Palmes ED et al., 1959, Inhalation toxicity of cobalt hydrocarbonyl. American Industrial Hygiene Association Journal, 20: 453-468
Molybdenum substances
Absorption
Based on numerous published human toxicokinetic studies, the toxicokinetics of molybdenum are well understood. The use of dual stable isotope (97Mo,100Mo) tracers has even allowed the establishment of sophisticated biokinetic models for molybdenum uptake, distribution and elimination. The modeling data indicate a highly efficient homeostatic mechanism over a wide range of intakes, suggesting diffusion rather than active transport as uptake mechanism:
Oral: Molybdenum absorption through the gastrointestinal occurs rapidly and almost completely (approx. 90% when given in water to fasted individuals), with little variation in absorption despite large variations in dose (i.e., between approx. 20-1400 µg/d orally). The absorption from the GI tract is not subject to any “saturation” at these dosages, with 90% at low and 94% at high intake levels. The relative bioavailability of food-bound Mo was 83% compared to “liquid” administration. Molybdenum levels in blood plasma peak quite early after oral administration. The influence of food matrix on intestinal absorption (100% from water by comparison) has been investigated by co-administration with solid food (50% absorption) and black tea (~10% absorption), for example(reference: Data Evaluation, Toxicokinetics, Molybdenum and its inorganic substances, EBRC unpublished report March 2010, EBRC Hannover, Germany).
Inhalation: Relevant animal or human data on inhalation absorption data are not available for molybdenum compounds. Inhalation absorption is a complex issue and cannot be strictly separated from exposure considerations. Due to the structure and nature of the respiratory tract, inhalation and deposition of particles in various regions of the respiratory tract is dependent on particle size characteristics such as size distribution and density, and will vary from species to species. Further, clearance mechanisms may need to be considered. However, as a worst case assumption, one may assume that soluble molybdenum substances are subject to complete systemic absorption after deposition.
Dermal: The dermal absorption of molybdenum is low to negligible, as has been shown in a guideline-conform in-vitro percutaneous absorption study conducted under GLP with the highly soluble substance sodium molybdate dihydrate (Roper, 2009).
Distribution: Upon uptake, the highly soluble molybdate anions are widely distributed in the body. The highest Mo concentrations are found in kidneys, liver and bone. However, there is no apparent accumulation of Mo in animal or human tissues and very little Mo seems to cross the placental barrier (Vyskocil & Viau, 1999).
Metabolism: Molybdenum is not subjected to any metabolism in its true sense: regardless of its original chemical speciation. Molybdenum transforms rather quickly to molybdate anions upon dissolution. In this form, it is available via diet or drinking water, and represents the physiologically relevant Mo species. Once systemically available, molybdenum is stable in the anionic molybdate form and not subject to any changes in speciation or valence.
Excretion
The elimination of molybdenum (in the form of highly soluble molybdate anions) from plasma is rapid and predominantly via renal excretion (>80%) and only to a lesser extent via faeces (<10%), indicating that the uptake of Mo is not regulated at the level of absorption. Neither the variation of Mo dietary intakes in the range 22-1490 µg/d nor an extended depletion/repletion period has been shown to have any statistically significant effect on serum or urinary copper levels, leaving copper absorption and retention largely unaltered (reference: Data Evaluation, Toxicokinetics, Molybdenum and its inorganic substances, EBRC unpublished report March 2010, EBRC Hannover, Germany).
References:
Vyskocil, A. and Viau, C. (1999) Assessment of molybdenum toxicity in humans, J. Appl.Toxicol. 19(3), 185-92
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.